3024 / 3581
2 bottom
Overall observer variation (SD)
Anatomical regions
Lymph nodes
GTV CT
GTV CT MRI
SD CT (mm)
SD CT (mm)
SD CT (mm)
All regions 3.6
4.4
3.3
Anterior
4.4
3.4
2.7
Dorsal
3.7
3.6
2.7
Caudal
4.6
7.7
3.5
Cranial
3.8
L-R
3.0
Parotid
4.0
Vertebrae
2.2
Vessels
2.3
Overall observer variation (SD)
Anatomical regions
Lymph nodes
SD CT (mm)
All regions 3.6
Level 1
3.1
Level 2
2.5
Level 3
2.1
Level 4
3.0
Level 5
6.1
Level 6
3.1
Prevertebral
3.1
Level 234
2.4
Phase III trial
60 patients early nasopharynx cancer
– T1-2, N0-1, M0
66, 60, 54 Gy 33 fractions, 6.6 week
– + brachytherapy boost if applicable
2DCRT versus IMRT
Mean parotid dose 61-32 Gy
•Kam et al JCO 2007
Phase III trial
•Kam et al JCO 2007
Is toxicity decreased ?
Various reports with retrospective
comparisons on salivary gland sparing
including randomized trials
No Phase III trial on safety performed yet